应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
09995 荣昌生物
已收盘 12-17 16:08:10
77.500
+1.200
+1.57%
最高
78.450
最低
75.600
成交量
196.23万
今开
76.400
昨收
76.300
日振幅
3.74%
总市值
436.80亿
流通市值
161.65亿
总股本
5.64亿
成交额
1.52亿
换手率
0.94%
流通股本
2.09亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
荣昌生物:第二届董事会第三十二次会议决议公告
证券日报 · 12-15 21:05
荣昌生物:第二届董事会第三十二次会议决议公告
荣昌生物(688331.SH)拟以2000万元至4000万元回购股份
智通财经 · 12-15 17:32
荣昌生物(688331.SH)拟以2000万元至4000万元回购股份
恒生医疗保健指数跌幅扩大至2.75% 医药股普遍走低 科伦博泰生物(06990)跌超7%
金吾财讯 · 12-15 11:11
恒生医疗保健指数跌幅扩大至2.75% 医药股普遍走低 科伦博泰生物(06990)跌超7%
智通港股空仓持单统计|12月12日
智通财经 · 12-12
智通港股空仓持单统计|12月12日
【券商聚焦】交银国际:创新药增量支付空间持续扩大
金吾财讯 · 12-12
【券商聚焦】交银国际:创新药增量支付空间持续扩大
每日卖空追踪 | 荣昌生物 12月11日卖空量成交56.05万股,卖空比例为8.78%
市场透视 · 12-11
每日卖空追踪 | 荣昌生物 12月11日卖空量成交56.05万股,卖空比例为8.78%
荣昌生物12月11日主力净流入1512.0万元 散户资金抛售
市场透视 · 12-11
荣昌生物12月11日主力净流入1512.0万元 散户资金抛售
港股异动 | 荣昌生物(09995)盘中涨超7% 公布PD-1/VEGF双抗非小细胞肺癌临床数据
智通财经 · 12-11
港股异动 | 荣昌生物(09995)盘中涨超7% 公布PD-1/VEGF双抗非小细胞肺癌临床数据
异动解读 | 荣昌生物港股通持股占比增加,盘中大涨5.05%
异动解读 · 12-11
异动解读 | 荣昌生物港股通持股占比增加,盘中大涨5.05%
港股生物医药股盘初走高!昭衍新药涨超7%,荣昌生物涨超6%
老虎资讯综合 · 12-11
港股生物医药股盘初走高!昭衍新药涨超7%,荣昌生物涨超6%
每日卖空追踪 | 荣昌生物 12月09日卖空量成交17.95万股,卖空比例为2.69%
市场透视 · 12-09
每日卖空追踪 | 荣昌生物 12月09日卖空量成交17.95万股,卖空比例为2.69%
荣昌生物12月09日遭主力抛售1278.5万元
市场透视 · 12-09
荣昌生物12月09日遭主力抛售1278.5万元
1000亿美元授权交易的背后:中国创新药全球价值突围
制药网 · 12-09
1000亿美元授权交易的背后:中国创新药全球价值突围
【券商聚焦】交银国际:2025年医保+商保双目录落地 多元支付体系盘活创新药增量空间
金吾财讯 · 12-09
【券商聚焦】交银国际:2025年医保+商保双目录落地 多元支付体系盘活创新药增量空间
每日卖空追踪 | 荣昌生物 12月08日卖空量成交77.6万股,卖空比例为5.83%
市场透视 · 12-08
每日卖空追踪 | 荣昌生物 12月08日卖空量成交77.6万股,卖空比例为5.83%
跨国巨头抄底中国创新药
21世纪经济报道 · 12-08
跨国巨头抄底中国创新药
港股生物医药股重挫!荣昌生物跌超12%,银诺医药跌超11%
老虎资讯综合 · 12-08
港股生物医药股重挫!荣昌生物跌超12%,银诺医药跌超11%
医药行业2025Q3持仓分析:医药持仓环比略降低 医药主动基金加仓其他生物制品、减仓化学制剂
西南证券 · 12-08
医药行业2025Q3持仓分析:医药持仓环比略降低 医药主动基金加仓其他生物制品、减仓化学制剂
80%、50种,我国医保目录成为创新药快速落地“加速器”
动脉网 · 12-07
80%、50种,我国医保目录成为创新药快速落地“加速器”
张卓莉教授:泰它西普中国III期研究数据发布,重塑干燥综合征治疗格局
动脉网 · 12-06
张卓莉教授:泰它西普中国III期研究数据发布,重塑干燥综合征治疗格局
公司概况
公司名称:
荣昌生物
所属市场:
SEHK
上市日期:
--
主营业务:
荣昌生物制药(烟台)股份有限公司是一家主要从事生物医药研究、生物医药服务及生物医药生产和销售的中国公司。该公司专注于抗体药物偶联物(ADC)、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。该公司的主要产品包括泰它西普、维迪西妥单抗、RC28-E等。该公司的产品主要应用于自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域。该公司主要在中国国内和海外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":77.5,"timestamp":1765958890011,"preClose":76.3,"halted":0,"volume":1962300,"delay":0,"floatShares":208581239,"shares":563608243,"eps":-3.017084513177957,"marketStatus":"已收盘","change":1.2,"latestTime":"12-17 16:08:10","open":76.4,"high":78.45,"low":75.6,"amount":151979646,"amplitude":0.037353,"askPrice":77.55,"askSize":500,"bidPrice":77.5,"bidSize":16000,"shortable":3,"etf":0,"ttmEps":-1.9287292959050315,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766021400000},"marketStatusCode":5,"adr":0,"listingDate":1604851200000,"exchange":"SEHK","adjPreClose":76.3,"openAndCloseTimeList":[[1765935000000,1765944000000],[1765947600000,1765958400000]],"volumeRatio":0.494254,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":81.9,"timestamp":1765954800000,"preClose":80.9,"halted":0,"volume":3087500,"delay":0,"premium":"-14.38"}},"requestUrl":"/m/hq/s/09995/wiki","defaultTab":"wiki","newsList":[{"id":"2591641505","title":"荣昌生物:第二届董事会第三十二次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2591641505","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591641505?lang=zh_cn&edition=full","pubTime":"2025-12-15 21:05","pubTimestamp":1765803918,"startTime":"0","endTime":"0","summary":"证券日报网讯12月15日晚间,荣昌生物发布公告称,公司第二届董事会第三十二次会议审议通过《关于以集中竞价交易方式回购公司股份方案的议案》等多项议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153591974866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2148510915.USD","LU1064131003.USD","LU1969619763.USD","688331","BK1583","09995","LU2488822045.USD","LU1064130708.USD","BK1161","BK0239","BK1574","LU2328871848.SGD"],"gpt_icon":0},{"id":"2591054614","title":"荣昌生物(688331.SH)拟以2000万元至4000万元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2591054614","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591054614?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:32","pubTimestamp":1765791179,"startTime":"0","endTime":"0","summary":"智通财经APP讯,荣昌生物(688331.SH)发布公告,公司拟以2000万元至4000万元回购股份,回购股份价格不超过95元/股,回购的股份拟用于员工持股计划或股权激励。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1969619763.USD","LU1064131003.USD","LU2488822045.USD","688331","BK0239","BK1161","09995","LU1064130708.USD","BK1574","LU2148510915.USD","BK1583","LU2328871848.SGD"],"gpt_icon":0},{"id":"2591691376","title":"恒生医疗保健指数跌幅扩大至2.75% 医药股普遍走低 科伦博泰生物(06990)跌超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591691376","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591691376?lang=zh_cn&edition=full","pubTime":"2025-12-15 11:11","pubTimestamp":1765768311,"startTime":"0","endTime":"0","summary":"金吾财讯 | 恒生医疗保健指数跌幅扩大至2.75%,医药股普遍走低,科伦博泰生物(06990)跌7.07%,百济神州(06160)跌5.35%,复宏汉霖(02696)跌5.32%,荣昌生物(09995)跌4.05%,康方生物(09926)跌3.61%。","market":"us","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971535","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2778985437.USD","HK0000165453.HKD","LU0348767384.USD","LU0417516571.SGD","BK1574","LU0348735423.USD","LU0561508036.HKD","LU0196878994.USD","LU2476274308.USD","LU1961090484.USD","LU0634319403.HKD","LU0588546209.SGD","LU0348825331.USD","LU1251922891.USD","159938","LU0348783233.USD","BK1583","LU0417516738.SGD","09939","IE00BPRC5H50.USD","LU2488822045.USD","BK1161","09995","06990","IE00B543WZ88.USD","LU2476274720.SGD","LU1303224171.USD","LU2399975544.HKD","LU1969619763.USD","LU0348784397.USD","LU0540923850.HKD","BK1515","LU0307460666.USD","BK1588","LU1719994722.HKD","06160","LU0348766576.USD","159506","LU0348827113.USD","LU1770034418.SGD","LU2328871848.SGD","09926","LU1794554557.SGD","BK1500","02696","IE00B5MMRT66.SGD","LU0417516902.SGD","LU1720050803.USD"],"gpt_icon":0},{"id":"2590570693","title":"智通港股空仓持单统计|12月12日","url":"https://stock-news.laohu8.com/highlight/detail?id=2590570693","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590570693?lang=zh_cn&edition=full","pubTime":"2025-12-12 18:30","pubTimestamp":1765535405,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,截止12月5日,未平仓空单比位列前三位为万科企业、中兴通讯、中远海控,空仓比分别为20.57%、17.63%、17.59%。智通机器人根据港交所数据,经过人工智能运算后自动生成,并不保证数据100%准确;以上涉及的空仓比增加值或减少值为绝对值数。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06865","00354","LU0315179316.USD","09863","82318","01072","LU2242644610.SGD","06613","01880","601318","IE00BZ08YR35.GBP","06680","02899","HK0000306685.HKD","09995","LU0235996351.USD","PAImain","01138","02228","01801","LU2097828631.EUR","LU0417516738.SGD","SG9999004220.SGD","01530","00863","HPAD.SI","LU2476274720.SGD","02382","LU1481107354.HKD","SG9999002463.SGD","01919","02498","09626","PNGAY","LU0320764599.SGD","LU0821914370.USD","LU0370786039.SGD","00763","02013","LU0348767384.USD","LU1211504680.USD","00522","000002","00839","01276","02202","03145"],"gpt_icon":1},{"id":"2590233595","title":"【券商聚焦】交银国际:创新药增量支付空间持续扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2590233595","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590233595?lang=zh_cn&edition=full","pubTime":"2025-12-12 09:02","pubTimestamp":1765501348,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示,10月以来,内资通过港股通持有医药股的比例小幅下降,外资持仓整体平稳,内外资加大创新药布局的大方向不变。该机构指,本周医保+商保双目录落地,医保谈判新增品种成功率创近年新高,续约品种降价幅度相对温和。该机构认为商保资金的引入将为创新药支付带来重要增量资金,进一步优化多元支付体系。该机构看好医保新纳入品种/适应症在2026年的销售放量,以及首版商保目录的实际执行和支付情况。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971425","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004220.SGD","LU2242644610.SGD","LU1993786604.SGD","LU2097828714.EUR","LU1794554557.SGD","LU1951186391.HKD","LU2778985437.USD","BK1588","02616","159992","LU0540923850.HKD","LU0708995583.HKD","01877","LU1770034418.SGD","BK1161","LU0456827905.SGD","02142","LU1242518931.SGD","06160","06978","LU1226287529.USD","LU0348766576.USD","02269","LU0359201612.USD","01801","LU0417516738.SGD","LU1969619763.USD","LU0181495838.USD","LU1961090484.USD","IE00B0JY6N72.USD","LU0043850808.USD","LU0880133367.SGD","LU2097828631.EUR","09926","LU2039709279.SGD","01177","LU2328871848.SGD","LU0516423091.SGD","LU0502904849.HKD","SG9999002463.SGD","HK0000165453.HKD","09688","LU0634319403.HKD","LU2097828557.USD","LU0359202008.SGD","01093","06185","LU0067412154.USD","03329","09995"],"gpt_icon":0},{"id":"2590596923","title":"每日卖空追踪 | 荣昌生物 12月11日卖空量成交56.05万股,卖空比例为8.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590596923","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590596923?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:30","pubTimestamp":1765441841,"startTime":"0","endTime":"0","summary":"荣昌生物北京时间12月11日,涨1.36%,卖空量成交56.05万股,较上一交易日增加34.57%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211163749a69916e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211163749a69916e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU1969619763.USD","LU2328871848.SGD","BK1574","09995","BK1161"],"gpt_icon":0},{"id":"2590596992","title":"荣昌生物12月11日主力净流入1512.0万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2590596992","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590596992?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:15","pubTimestamp":1765440921,"startTime":"0","endTime":"0","summary":"12月11日, 荣昌生物股价涨1.36%,报收78.25元,成交金额5.1亿元,换手率3.06%,振幅7.25%,量比1.08。荣昌生物今日主力资金净流入1512.0万元,上一交易日主力净流出1408.8万元。该股近5个交易日下跌12.49%,主力资金累计净流出9071.8万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流入522.1万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211161638a441f0ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211161638a441f0ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09995","BK1161","LU2328871848.SGD","BK1583","LU1969619763.USD"],"gpt_icon":0},{"id":"2590563981","title":"港股异动 | 荣昌生物(09995)盘中涨超7% 公布PD-1/VEGF双抗非小细胞肺癌临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2590563981","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590563981?lang=zh_cn&edition=full","pubTime":"2025-12-11 10:45","pubTimestamp":1765421137,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,荣昌生物盘中涨超7%,截至发稿,涨5.57%,报81.5港元,成交额3.1亿港元。会上,由荣昌生物自主研发的PD-1/VEGF双特异性抗体RC148单药及联合方案一线或二线治疗非小细胞肺癌的一项Ⅰ/Ⅱ期临床研究数据,以壁报形式正式发布。据悉,今年8月,RC148已获FDA批准在美国开展II期临床试验。获得FDA的IND许可,标志着该药将进入全球临床开发阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380238.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131003.USD","LU1969619763.USD","PD","LU2328871848.SGD","688331","BK1574","BK1583","LU1169590202.USD","LU2488822045.USD","BK1161","09995","LU1169589451.USD","BK0239","LU2148510915.USD","LU1064130708.USD","BK4023"],"gpt_icon":0},{"id":"1187104054","title":"异动解读 | 荣昌生物港股通持股占比增加,盘中大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187104054","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187104054?lang=zh_cn&edition=full","pubTime":"2025-12-11 09:40","pubTimestamp":1765417219,"startTime":"0","endTime":"0","summary":"今日盘中,荣昌生物(09995)股价大幅上涨5.05%,表现亮眼。消息面上,根据最新港股通持股数据显示,荣昌生物的港股通持股占比增加了0.63%,达到50.63%。这表明内地投资者通过港股通渠道对该股的买入兴趣增强,可能是推动其股价上涨的重要因素。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5863422ac1bd6abc1efb51c1b10288a9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"gpt_icon":0},{"id":"1132076924","title":"港股生物医药股盘初走高!昭衍新药涨超7%,荣昌生物涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1132076924","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132076924?lang=zh_cn&edition=full","pubTime":"2025-12-11 09:38","pubTimestamp":1765417090,"startTime":"0","endTime":"0","summary":"12月11日,港股生物医药股盘初走高,$荣昌生物(09995)$涨超4%,$康方生物(09926)$、$药明生物(02269)$、$药明合联(02268)$、$药明康德(02359)$均涨超2%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5863422ac1bd6abc1efb51c1b10288a9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","02268","09939","02269","09926","06127"],"gpt_icon":0},{"id":"2590328636","title":"每日卖空追踪 | 荣昌生物 12月09日卖空量成交17.95万股,卖空比例为2.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590328636","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590328636?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:30","pubTimestamp":1765269041,"startTime":"0","endTime":"0","summary":"荣昌生物北京时间12月09日,跌4.73%,卖空量成交17.95万股,较上一交易日减少83.49%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163657a72cf3b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163657a72cf3b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","LU2328871848.SGD","LU1969619763.USD","BK1583","BK1161","09995"],"gpt_icon":0},{"id":"2590661328","title":"荣昌生物12月09日遭主力抛售1278.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590661328","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590661328?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:16","pubTimestamp":1765268164,"startTime":"0","endTime":"0","summary":"12月09日, 荣昌生物股价跌4.73%,报收75.50元,成交金额5.1亿元,换手率3.20%,振幅6.94%,量比1.43。荣昌生物今日主力资金净流出1278.5万元,连续3日净流出,上一交易日主力净流出6550.0万元。该股近5个交易日下跌12.14%,主力资金累计净流出8181.6万元;近20日主力资金累计净流入1447.4万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209162320a72ceb1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209162320a72ceb1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","LU2328871848.SGD","LU1969619763.USD","BK1583","09995"],"gpt_icon":0},{"id":"2590181443","title":"1000亿美元授权交易的背后:中国创新药全球价值突围","url":"https://stock-news.laohu8.com/highlight/detail?id=2590181443","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590181443?lang=zh_cn&edition=full","pubTime":"2025-12-09 11:43","pubTimestamp":1765251807,"startTime":"0","endTime":"0","summary":"恒瑞医药与GSK的120亿美元合作协议落定,当信达生物与武田制药114亿美元的联手刷屏行业,2025年中国创新药对外授权交易迎来爆发。有数据显示,仅2025年前三季度,中国创新药对外授权总金额已突破1000亿美元。而授权交易数据的爆发式增长,直观展现了全球市场对中国创新价值的认可。业内表示,中国创新药的价值跃升,本质是研发实力与成本优势的双重赋能。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209114610a72c6f9e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209114610a72c6f9e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01530","LU2097828474.EUR","BK1583","LU2097828805.USD","HK0000165453.HKD","BK1161","LU2242644610.SGD","01276","06978","BK1589","LU1969619763.USD","LU2097828557.USD","09995","LU0502904849.HKD","03692","LU2097828631.EUR","LU2097828714.EUR","LU2328871848.SGD","LU0455707207.USD","LU2488822045.USD","BK1574","01801"],"gpt_icon":0},{"id":"2590367035","title":"【券商聚焦】交银国际:2025年医保+商保双目录落地 多元支付体系盘活创新药增量空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2590367035","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590367035?lang=zh_cn&edition=full","pubTime":"2025-12-09 08:59","pubTimestamp":1765241994,"startTime":"0","endTime":"0","summary":"调整后的目录中,药品总数增至3,253种。新版目录将于2026年1月1日正式实施。该机构认为,更多新药进入目录有助于提升临床用药水平,及创新药行业整体研发回报率;商保资金的引入将为创新药支付带来重要增量资金,为多元化支付体系的建立奠定基础。百济有两款产品纳入商保创新药目录,信达、和黄各有一款纳入。同时重点关注首批商保目录的实际执行和支付情况、名单及定价的动态调整以及真实世界数据积累带来的长期发展机会。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971149","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0181495838.USD","LU0348766576.USD","LU1719994722.HKD","LU0140636845.USD","09926","BK1161","LU0326950275.SGD","LU0572944931.SGD","BK1588","LU0880133367.SGD","IE00B0JY6N72.USD","IE00BZ08YR35.GBP","LU0417516902.SGD","LU1813983027.USD","159992","BK1147","01177","BK1574","LU0327786744.USD","03329","LU0348784397.USD","LU1226288170.HKD","LU2039709279.SGD","LU1770034418.SGD","02142","01801","LU0708995583.HKD","LU1720050803.USD","BK1141","LU0348767384.USD","LU0456827905.SGD","BK1576","01877","02616","BK1610","09995","06160","LU2476274308.USD","06185","09688","LU1969619763.USD","BK1191","01093","LU0516423091.SGD","02269","LU0348783233.USD","LU1951186391.HKD","LU2399975544.HKD","06978","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2589356374","title":"每日卖空追踪 | 荣昌生物 12月08日卖空量成交77.6万股,卖空比例为5.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589356374","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589356374?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:30","pubTimestamp":1765182640,"startTime":"0","endTime":"0","summary":"荣昌生物北京时间12月08日,跌10.3%,卖空量成交77.6万股,较上一交易日增加852.15%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208163649a72ab0c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208163649a72ab0c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","BK1574","BK1161","LU2328871848.SGD","09995","BK1583"],"gpt_icon":0},{"id":"2589356587","title":"跨国巨头抄底中国创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2589356587","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589356587?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:14","pubTimestamp":1765181695,"startTime":"0","endTime":"0","summary":"产业领域的跨国公司在行业最为低迷之际仍在进行抄底操作,这是因为其洞察到中国创新药产业在底层的创新能力、研发能力以及临床能力均在持续提升,这便是今年上半年众多跨国公司纷纷展开大规模收购行动的缘由。数据显示,2025年前三季度,中国创新药板块上市公司整体实现营业收入488.3亿元,同比增长22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208162028a72aa660&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208162028a72aa660&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU1969619763.USD","01276","01801","LU2328871848.SGD","BK1574","09995","BK1161","06978","03692"],"gpt_icon":0},{"id":"1157903379","title":"港股生物医药股重挫!荣昌生物跌超12%,银诺医药跌超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157903379","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157903379?lang=zh_cn&edition=full","pubTime":"2025-12-08 09:57","pubTimestamp":1765159066,"startTime":"0","endTime":"0","summary":"12月8日,港股生物医药股重挫,$荣昌生物(688331)$跌超12%,$银诺医药-B(02591)$跌超11%,$信达生物(01801)$、$乐普生物-B(02157)$、$来凯医药-B(02105)$跌超6%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ea7f8bad5830eb56e7f8e7357923f6c6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064130708.USD","LU2488822045.USD","BK1574","BK1161","LU2328871848.SGD","LU1969619763.USD","LU2148510915.USD","BK0239","02591","BK1583","LU1064131003.USD","09995"],"gpt_icon":0},{"id":"2589358833","title":"医药行业2025Q3持仓分析:医药持仓环比略降低 医药主动基金加仓其他生物制品、减仓化学制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2589358833","media":"西南证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589358833?lang=zh_cn&edition=full","pubTime":"2025-12-08 00:00","pubTimestamp":1765123200,"startTime":"0","endTime":"0","summary":"2025Q3医药总持仓变化情况:25Q3全部公募基金占比9.67%,环比-0.21pp;剔除主动医药基金占比6.74%,环比-0.74pp;再剔除指数基金医药持仓占比5.13%,环比+0.73pp;申万医药板块市值占比为7.83%,环比+1.52pp。2025Q3医药基金医药子行业重仓市值占比变化情况:环比增加前三:其他生物制品占比14.3%,环比增加最大,+3.43pp;医疗研发外包占比9.2%,环比+1.65pp,疫苗占比0.01%,环比+0.01pp。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208150631a43aca57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208150631a43aca57&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1961090484.USD","LU0634319403.HKD","LU2488822045.USD","IE00BPRC5H50.USD","09995","09939","LU2778985437.USD","LU2476274720.SGD","01530","IE00B5MMRT66.SGD","LU0348735423.USD","LU0540923850.HKD","BK1161","LU0348766576.USD","BK1515","LU0417516902.SGD","LU2476274308.USD","LU1720050803.USD","LU0348767384.USD","LU0561508036.HKD","LU2399975544.HKD","LU1794554557.SGD","IE00B543WZ88.USD","LU0348825331.USD","LU0417516738.SGD","LU0417516571.SGD","09926","LU0348783233.USD","LU0348784397.USD","BK1574","LU0348827113.USD"],"gpt_icon":0},{"id":"2589380386","title":"80%、50种,我国医保目录成为创新药快速落地“加速器”","url":"https://stock-news.laohu8.com/highlight/detail?id=2589380386","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589380386?lang=zh_cn&edition=full","pubTime":"2025-12-07 23:22","pubTimestamp":1765120920,"startTime":"0","endTime":"0","summary":"我国已建立每年一调的医保目录动态调整机制,聚焦5年内新上市药品。2025年新纳入的114种药品中,多个实现当年获批上市即进目录。2018年以来,我国1类创新药获批数量明显上升,2024年达48种,医保目录成其快速落地“加速器”,推动市场扩容。药企研发投入有稳定回报预期,将激励更多药企加大创新研发,尤其针对肿瘤、罕见病等未满足需求领域。新药从获批到纳入医保报销的时间从5年缩短至1年左右,约80%的创新药能在上市两年内进目录。医保准入成市场拓展关键,通过“腾笼换鸟”优化资源配置,推动医药行业向高质量、创新型转型。目前,2025年国家医保药品目录内药品总数达3253种,1类创新药增至50种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512072346299794c403&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512072346299794c403&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","09926","BK1161","09995","BK1574","01877","BK1583","LU1969619763.USD","LU2328871848.SGD","06160","06978"],"gpt_icon":0},{"id":"2589823172","title":"张卓莉教授:泰它西普中国III期研究数据发布,重塑干燥综合征治疗格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2589823172","media":"动脉网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589823172?lang=zh_cn&edition=full","pubTime":"2025-12-06 17:53","pubTimestamp":1765014780,"startTime":"0","endTime":"0","summary":"干燥综合征缺乏有效靶向药,临床管理以缓解局部症状为主,生物制剂带来新希望。这一成果证实泰它西普通过双靶点机制调控疾病,为临床实践等注入新动力。张卓莉教授称,ESSDAI评分降低4分以上,意味着与疾病相关的多系统炎症和免疫异常得到广泛深度抑制,标志着对干燥综合征全身疾病活动度的控制取得重大进步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206180551a7277360&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206180551a7277360&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","LU2328871848.SGD","BK1583","BK1574","BK1161","09995"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0106},{"period":"1month","weight":-0.1071},{"period":"3month","weight":-0.2815},{"period":"6month","weight":0.5291},{"period":"1year","weight":3.7041},{"period":"ytd","weight":4.2986}],"compareEarnings":[{"period":"1week","weight":-0.0078},{"period":"1month","weight":-0.0679},{"period":"3month","weight":-0.0622},{"period":"6month","weight":0.086},{"period":"1year","weight":0.2748},{"period":"ytd","weight":0.258}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"荣昌生物制药(烟台)股份有限公司是一家主要从事生物医药研究、生物医药服务及生物医药生产和销售的中国公司。该公司专注于抗体药物偶联物(ADC)、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。该公司的主要产品包括泰它西普、维迪西妥单抗、RC28-E等。该公司的产品主要应用于自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.166095},{"month":2,"riseRate":0.8,"avgChangeRate":0.209338},{"month":3,"riseRate":0.4,"avgChangeRate":-0.022811},{"month":4,"riseRate":0.8,"avgChangeRate":0.104301},{"month":5,"riseRate":0.4,"avgChangeRate":-0.023394},{"month":6,"riseRate":0.8,"avgChangeRate":0.127757},{"month":7,"riseRate":0.6,"avgChangeRate":-0.032319},{"month":8,"riseRate":0.4,"avgChangeRate":0.068611},{"month":9,"riseRate":0.6,"avgChangeRate":0.099222},{"month":10,"riseRate":0.4,"avgChangeRate":0.027845},{"month":11,"riseRate":1,"avgChangeRate":0.038747},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.045757}],"exchange":"SEHK","name":"荣昌生物","nameEN":"REMEGEN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,09995,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}